The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.
The blood screening market plays a critical role in ensuring the safety and quality of blood used for transfusions and medical procedures. It involves the detection of infectious agents such as HIV, hepatitis B and C, and other transfusion-transmissible infections, helping to prevent disease transmission. The market is driven by increasing awareness of blood safety, rising demand for blood donations, and technological advancements in screening methods such as nucleic acid testing and rapid diagnostics. With growing healthcare investments and supportive government initiatives, the blood screening market is expanding globally, particularly in emerging economies. As the need for accurate and efficient blood testing continues to rise, the market is expected to experience sustained growth across various healthcare settings.
Continue reading for more details: https://www.fortunebusinessinsights.com/blood-screening-market-102552
Market Segmentation:
Product Type: The market is segmented into reagents & kits, instruments, and software & services. Reagents and kits dominate due to their routine use in screening procedures.
Technology: Includes nucleic acid testing (NAT), enzyme-linked immunosorbent assay (ELISA), rapid tests, and western blot assays. NAT is witnessing rapid growth due to its high sensitivity and specificity.
Application: The blood screening market covers infectious disease detection, blood group typing, and genetic disease screening. Infectious disease screening holds the largest share.
End User: Key segments include blood banks, hospitals, diagnostic laboratories, and clinics. Blood banks are the major end users due to the high volume of blood donations.
List Of Key Companies Profiled:
Bio-Rad Laboratories, Inc.
Grifols, S.A.
Hoffmann-La Roche
Ortho Clinical Diagnostics
BD
DiaSorin S.p.A.
Thermo Fisher Scientific Inc.
Abbott
QUOTIENT
Other Players
Market Growth:
The blood screening market is experiencing steady expansion due to the increasing demand for safe blood transfusions and the rising prevalence of infectious diseases.
Technological advancements in molecular diagnostics and automation have significantly contributed to the market's growth.
Growing awareness about early disease detection and preventative healthcare is fueling the demand for blood screening market
Supportive government initiatives and investments in healthcare infrastructure are also accelerating market development.
The increased need for screening during pandemics and outbreaks has further propelled the blood screening market
Restraining Factors:
High costs associated with advanced screening technologies pose a challenge to market expansion, especially in developing regions.
Stringent regulatory requirements and time-consuming approval processes for new screening products can delay market entry.
Lack of skilled professionals to operate complex diagnostic equipment hampers the growth of the blood screening market in some areas.
Limited awareness and healthcare access in low-income regions also restrict widespread adoption of blood screening market tools.
Regional Analysis:
North America leads the blood screening market due to well-established healthcare systems, frequent blood donations, and strong regulatory frameworks.
Europe follows closely, supported by advanced diagnostics infrastructure and high awareness regarding transfusion safety.
Asia-Pacific is projected to witness the fastest growth owing to rising healthcare spending, increasing blood donations, and government initiatives for disease control.
Latin America and Middle East & Africa are emerging regions with growing potential but face challenges related to infrastructure and affordability in the blood screening market.
Contact us:
Fortune Business Insights™ Pvt.
Phone: USA: +1 833 909 2966 (Toll-Free),
United Kingdom: +44 808 502 0280 (Toll-Free)
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com